REITHERA Email Format
Biotechnology ResearchLazio, Italy51-200 Employees
ReiThera Srl operates as a contract development and manufacturing organization focused on technology and process development and GMP manufacturing to support the clinical translation of genetic vaccines and other advanced therapies. The company has broad expertise in scalable viral-vector manufacturing and GMP production across multiple vector platforms, enabling clinical-grade supply for early-stage programs. Its core production capacity is housed in a modern facility in Rome, featuring several scales of stirred-tank bioreactors, fixed-bed systems for adherent cell growth, a filling suite, and quality control laboratories. ReiThera serves biotechnology and pharmaceutical developers seeking manufacturing and development support for genetic vaccines and other advanced therapies, helping move candidates toward the clinic. In early 2025, the company announced a Master Service Agreement with SillaJen to manufacture the SJ-600 anticancer virus platform, reflecting active collaboration with partners in the field.